Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

ABSTRACT:

Objective

To evaluate the efficacy and safety of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without carboplatin as adjuvant therapy for patients with high risk, early stage, triple negative breast cancer.

Design

Randomised, open label, phase 3 trial.

Setting

Fudan University Shanghai Cancer Center in China between March 2020 and March 2022.

Participants

Female patients with operable high risk triple negative breast cancer (defined as either regional node positive or node negative with a Ki-67 labelling index of ≥50%) after definitive surgery.

Interventions

Patients were randomised in a 1:1 ratio into either the carboplatin arm (four cycles of two weekly epirubicin and cyclophosphamide followed by four cycles of weekly paclitaxe

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12723525 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature